![Peter Blume-Jensen](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Peter Blume-Jensen
Directeur Général chez
ACRIVON THERAPEUTICS, INC.
Fortune : 4 M $ au 31/05/2026
Profil
Peter Blume-Jensen is the founder of Acrivon Therapeutics, Inc., founded in 2018, where the title held is Chairman, President & Chief Executive Officer.
The current job is Scientific & Clinical Advisor at Metamark Genetics, Inc. since 2010.
Former jobs include Exec Director & VP-External Scientific Affairs at Daiichi Sankyo, Inc. from 2008 to 2012; Principal at Merck & Co., Inc.; Principal at EMD Serono, Inc. from 2001 to 2008; Principal at Merck Research Laboratories Massachusetts LLC; and Chief Scientific Officer at XTuit Pharmaceuticals, Inc. from 2014 to 2018.
Education includes a doctorate from the University of Copenhagen.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 21/05/2026 | 2 245 317 ( 5,25% ) | 4 M $ | 31/05/2026 |
Postes actifs de Peter Blume-Jensen
| Sociétés | Poste | Début |
|---|---|---|
| ACRIVON THERAPEUTICS, INC. | Directeur Général | 01/04/2018 |
Metamark Genetics, Inc.
 Metamark Genetics, Inc. Medical/Nursing ServicesHealth Services Provides molecular diagnostics services | Corporate Officer/Principal | - |
Anciens postes connus de Peter Blume-Jensen
| Sociétés | Poste | Fin |
|---|---|---|
XTuit Pharmaceuticals, Inc.
 XTuit Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops drugs for the treatment of cancer | Directeur Technique/Scientifique/R&D | 01/01/2018 |
EMD Serono, Inc.
 EMD Serono, Inc. Pharmaceuticals: MajorHealth Technology Develops recombinant prescription medicines | Corporate Officer/Principal | - |
| MERCK & CO., INC. | Corporate Officer/Principal | - |
Daiichi Sankyo, Inc.
 Daiichi Sankyo, Inc. Pharmaceuticals: MajorHealth Technology Manufactures and supplies pharmaceutical products | Directeur/Membre du Conseil | - |
Merck Research Laboratories Massachusetts LLC
 Merck Research Laboratories Massachusetts LLC Pharmaceuticals: MajorHealth Technology Discovers, develops, and markets a broad range of human and animal health products | Corporate Officer/Principal | - |
Formation de Peter Blume-Jensen
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
49
Relations au 1er degré
8
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 8 |
|---|---|
Merck & Co., Inc.
 Merck & Co., Inc. Pharmaceuticals: MajorHealth Technology Manufactures human and animal health pharmaceutical products & vaccines | Health Technology |
Metamark Genetics, Inc.
Metamark Genetics, Inc. Medical/Nursing ServicesHealth Services Provides molecular diagnostics services | Health Services |
EMD Serono, Inc.
EMD Serono, Inc. Pharmaceuticals: MajorHealth Technology Develops recombinant prescription medicines | Health Technology |
University of Copenhagen
 University of Copenhagen Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Merck Research Laboratories Massachusetts LLC
Merck Research Laboratories Massachusetts LLC Pharmaceuticals: MajorHealth Technology Discovers, develops, and markets a broad range of human and animal health products | Health Technology |
Daiichi Sankyo, Inc.
Daiichi Sankyo, Inc. Pharmaceuticals: MajorHealth Technology Manufactures and supplies pharmaceutical products | Health Technology |
XTuit Pharmaceuticals, Inc.
XTuit Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops drugs for the treatment of cancer | Health Technology |
Acrivon Therapeutics, Inc.
 Acrivon Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical stage biopharmaceutical company that develops and sells precision oncology medicines | Health Technology |
